213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma

Journal of Nuclear Medicine

Volumn 54, Issue 9, 2013, Pages 1597-1604

  Chérel, Michel ^a,b   Gouard, Sébastien ^a   Gaschet, Joëlle ^a,b   Saï Maurel, Catherine ^a   Bruchertseifer, Frank ^c   Morgenstern, Alfred ^c   Bourgeois, Mickael ^a,d   Gestin, Jean François ^a,b   Bodéré, Françoise Kraeber ^a,b,d   Barbet, Jacques ^a   Moreau, Philippe ^a,d   Davodeau, François ^a,d  

^a UNIVERSITÉ DE NANTES   (France)

^b IRCNA   (France)

^c JOINT RESEARCH CENTRE   (Italy)

^d NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

5T33; A particle; CD138; Multiple myeloma; Oncology; Radioimmunotherapy

Indexed keywords

BISMUTH 213; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G2B ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD 138; SYNDECAN 1; UNCLASSIFIED DRUG; BISMUTH; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; SDC1 PROTEIN, MOUSE;

ALPHA RADIATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ARTICLE; BLOOD CELL COUNT; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; IMMUNOGLOBULIN BLOOD LEVEL; ISOTOPE LABELING; LINEAR ENERGY TRANSFER; LIVER TOXICITY; MINIMAL RESIDUAL DISEASE; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RADIOIMMUNOTHERAPY; SURVIVAL RATE; Α-PARTICLE; 5T33; ANIMAL; C57BL MOUSE; CD138; IMMUNOLOGY; METHODOLOGY; ONCOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

Α-PARTICLE; 213BI; 5T33; CD138; MULTIPLE MYELOMA; ONCOLOGY; RADIOIMMUNOTHERAPY;

ANIMALS; ANTIBODIES, MONOCLONAL; BISMUTH; CELL LINE, TUMOR; FEMALE; MICE; MICE, INBRED C57BL; MULTIPLE MYELOMA; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOPHARMACEUTICALS; SURVIVAL RATE; SYNDECAN-1; TREATMENT OUTCOME;

EID: 84887362097     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.111997     Document Type: Article

References (38)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351:1860-1873.
2. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046-1060.
3. Lonial S, Mitsiades CS, Richardson PG. Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res. 2011;17:1264-1277.
4. Liepe K. Alpharadin, a 223Ra-based alpha-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer. Curr Opin Investig Drugs. 2009;10:1346-1358.
5. Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood. 2002;100:1233-1239.
6. Huang YW, Richardson JA, Vitetta ES. Anti-CD54 (ICAM-1) has antitumor activity in SCID mice with human myeloma cells. Cancer Res. 1995;55:610-616.
7. Goto T, Kennel SJ, Abe M, et al. A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood. 1994;84:1922-1930.
8. Erikson E, Adam T, Schmidt S, et al. In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317/BST-2/HM1.24/ tetherin in humans. Proc Natl Acad Sci USA. 2011;108:13688-13693.
9. Klein B, Wijdenes J, Zhang XG, et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood. 1991;78:1198-1204.
10. Wijdenes J, Vooijs WC, Clement C, et al. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol. 1996;94:318-323.
11. Supiot S, Faivre-Chauvet A, Couturier O, et al. Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma. Cancer. 2002;94:1202-1209.
12. Bayer-Garner IB, Sanderson RD, Dhodapkar MV, Owens RB, Wilson CS. Syndecan- 1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Mod Pathol. 2001;14: 1052-1058.
13. Sanderson RD, Yang Y. Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin Exp Metastasis. 2008;25:149-159.
14. Bartl R, Frisch B, Diem H, et al. Histologic, biochemical, and clinical parameters for monitoring multiple myeloma. Cancer. 1991;68:2241-2250.
15. Radl J, Croese J, Zurcher C, et al. Animal model of human disease: multiple myeloma. Am J Pathol. 1988;132:593-597.
16. Onishi M, Kinoshita S, Morikawa Y, et al. Applications of retrovirus-mediated expression cloning. Exp Hematol. 1996;24:324-329.
17. Bernardeau K, Gouard S, David G, et al. Assessment of CD8 involvement in T cell clone avidity by direct measurement of HLA-A2/Mage3 complex density using a high-affinity TCR like monoclonal antibody. Eur J Immunol. 2005; 35:2864-2875.
18. Nikula TK, Curcio MJ, Brechbiel MW, Gansow OA, Finn RD, Scheinberg DA. A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies. Nucl Med Biol. 1995;22:387-390.
19. Apostolidis C, Molinet R, Rasmussen G, Morgenstern A. Production of Ac-225 from Th-229 for targeted alpha therapy. Anal Chem. 2005;77:6288-6291.
20. Jeon YH, Choi Y, Kang JH, et al. Immune response to firefly luciferase as a naked DNA. Cancer Biol Ther. 2007;6:781-786.
21. Stanford KI, Bishop JR, Foley EM, et al. Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. J Clin Invest. 2009;119:3236-3245.
22. Huchet A, Belkacemi Y, Frick J, et al. Plasma Flt-3 ligand concentration correlated with radiation-induced bone marrow damage during local fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2003;57:508-515.
23. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2:175-187.
24. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005;23:6333-6338.
25. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med. 2008;359:613-626.
26. Morschhauser F, Kraeber-Bodere F, Wegener WA, et al. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. J Clin Oncol. 2010;28:3709-3716.
27. Chérel M, Davodeau F, Kraeber-Bodere F, Chatal JF. Current status and perspectives in alpha radioimmunotherapy. Q J Nucl Med Mol Imaging. 2006;50:322-329.
28. Humm JL, Chin LM. A model of cell inactivation by alpha-particle internal emitters. Radiat Res. 1993;134:143-150.
29. Chouin N, Bernardeau K, Bardies M, et al. Evidence of extranuclear cell sensitivity to alpha-particle radiation using a microdosimetric model. II. Application of the microdosimetric model to experimental results. Radiat Res. 2009;171:664-673.
30. Park SI, Shenoi J, Pagel JM, et al. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. Blood. 2010;116:4231-4239.
31. Elgqvist J, Andersson H, Haglund E, et al. Intraperitoneal alpha-radioimmunotherapy in mice using different specific activities. Cancer Biother Radiopharm. 2009;24:509-513.
32. Andersson H, Cederkrantz E, Back T, et al. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of 211At-MX35 F(ab')2-a phase I study. J Nucl Med. 2009;50:1153-1160.
33. Pfost B, Seidl C, Autenrieth M, et al. Intravesical alpha- radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice. J Nucl Med. 2009;50:1700-1708.
34. Zalutsky MR, Reardon DA, Akabani G, et al. Clinical experience with alphaparticle emitting 211At: treatment of recurrent brain tumor patients with 211Atlabeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med. 2008;49:30-38.
35. Boskovitz A, McLendon RE, Okamura T, Sampson JH, Bigner DD, Zalutsky MR. Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting 211At-labeled trastuzumab. Nucl Med Biol. 2009;36:659-669.
36. Rousseau C, Ferrer L, Supiot S, et al. Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients. Tumour Biol. 2012;33:679-688.
37. Song H, Shahverdi K, Huso DL, et al. 213Bi (a-emitter): antibody targeting of breast cancer metastases in the neu-N transgenic mouse model. Cancer Res. 2008;68:3873-3880.
38. Prat M, Demarquay C, Frick J, Dudoignon N, Thierry D, Bertho JM. Use of flt3 ligand to evaluate residual hematopoiesis after heterogeneous irradiation in mice. Radiat Res. 2006;166:504-511.